Cell-Easy

Startup

Cell-Easy offers cryopreserved ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development projects (5 to 100M cells/dose). The formulation has been optimized to limit the operations at the point of care and allow for direct injection right after thawing. Cell-Easy also acts as a CDMO: process development and GMP production in aseptic and pharmaceutical conditions.



website